World's Best Scientists 2026 revealed!
James L. Abbruzzese

James L. Abbruzzese

D-Index & Metrics

Medicine

D-Index
147
Citations
76825
World Ranking
1295
National Ranking
747

James L. Abbruzzese publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where James L. Abbruzzese sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 725 publications — 83rd percentile

83% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

James L. Abbruzzese D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where James L. Abbruzzese sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 147 D-Index — 94th percentile

94% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

James L. Abbruzzese is affiliated with Duke University in the United States and has a significant body of work in the fields of medicine and biochemistry, genetics, and molecular biology. Their research primarily focuses on oncology, with substantial contributions to pancreatic and hepatic oncology, cancer genomics and diagnostics, as well as cancer immunotherapy and biomarkers.

Their main fields of study include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

They have focused on several subfields, notably:

  • Oncology
  • Molecular Biology
  • Immunology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Key research topics covered in their publications involve:

  • Pancreatic and Hepatic Oncology Research
  • Phagocytosis and Immune Regulation
  • Cancer Genomics and Diagnostics
  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Treatments and Mutations
  • PARP inhibition in cancer therapy
  • Ovarian cancer diagnosis and treatment

Their recent papers include:

  • Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial, 2022, The Lancet Oncology
  • Implementation of a Molecular Tumor Registry to Support the Adoption of Precision Oncology Within an Academic Medical Center: The Duke University Experience, 2021, JCO Precision Oncology
  • Genetic variants of the peroxisome proliferator-activated receptor (PPAR) signaling pathway genes and risk of pancreatic cancer, 2020, Molecular Carcinogenesis
  • Selective killing of cancer cells harboring mutant RAS by concomitant inhibition of NADPH oxidase and glutathione biosynthesis, 2021, Cell Death and Disease
  • Abstract CT145: Olaparib +/- atezolizumab in patients with BRCA-mutated (BRCAmt) locally advanced unresectable or metastatic (advanced) breast cancer: an open-label, multicenter, randomized phase II trial, 2023, Cancer Research

Frequent co-authors in their research include:

  • S. Percy Ivy
  • Elad Sharon
  • Mark M. Awad
  • John H. Strickler
  • Yongde Luo

Their work has frequently been published in journals such as:

  • Journal of Clinical Oncology
  • Cancer Research
  • Gynecologic Oncology
  • Cancers
  • The Lancet Oncology

Best Publications

  • The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis

    Gideon Steinbach;Patrick M. Lynch;Robin K S Phillips;Marina H. Wallace

  • Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer

    Navneet Dhillon;Bharat B. Aggarwal;Robert A. Newman;Robert A. Wolff

  • Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

    Mark J. Ratain;Tim Eisen;Walter M. Stadler;Keith T. Flaherty

  • Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer

    Thiruvengadam Arumugam;Vijaya Ramachandran;Keith Francis Fournier;Huamin Wang

  • Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy

    Gauri R. Varadhachary;Eric P. Tamm;James L. Abbruzzese;Henry Q. Xiong

  • A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.

    J L Abbruzzese;R Grunewald;E A Weeks;D Gravel

  • Risk factors for hepatocellular carcinoma: Synergism of alcohol with viral hepatitis and diabetes mellitus

    Manal M. Hassan;Lu Yu Hwang;Chiq J. Hatten;Mark Swaim

  • The Nuclear Factor-κB RelA Transcription Factor Is Constitutively Activated in Human Pancreatic Adenocarcinoma Cells

    Weixin Wang;James L. Abbruzzese;Douglas B. Evans;Lillie Larry

  • Metastatic patterns in adenocarcinoma

    Kenneth R. Hess;Gauri R. Varadhachary;Sarah H. Taylor;Wei Wei

  • Epidermal Growth Factor Receptor Cooperates with Signal Transducer and Activator of Transcription 3 to Induce Epithelial-Mesenchymal Transition in Cancer Cells via Up-regulation of TWIST Gene Expression

    Hui Wen Lo;Sheng Chieh Hsu;Weiya Xia;Xinyu Cao

  • Preoperative Gemcitabine-Based Chemoradiation for Patients With Resectable Adenocarcinoma of the Pancreatic Head

    Douglas B. Evans;Gauri R. Varadhachary;Christopher H. Crane;Charlotte C. Sun

  • Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205

    Philip A. Philip;Jacqueline Benedetti;Christopher L. Corless;Ralph Wong

  • Antidiabetic therapies affect risk of pancreatic cancer

    Donghui Li;Sai–Ching J. Yeung;Manal M. Hassan;Marina Konopleva

  • Acquisition of Epithelial-Mesenchymal Transition Phenotype of Gemcitabine-Resistant Pancreatic Cancer Cells Is Linked with Activation of the Notch Signaling Pathway

    Zhiwei Wang;Yiwei Li;Dejuan Kong;Sanjeev Banerjee

  • Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis

    Daoyan Wei;Xiangdong Le;Leizhen Zheng;Liwei Wang

  • Blockade of the Epidermal Growth Factor Receptor Signaling by a Novel Tyrosine Kinase Inhibitor Leads to Apoptosis of Endothelial Cells and Therapy of Human Pancreatic Carcinoma

    Christiane J. Bruns;Carmen C. Solorzano;Matthew T. Harbison;Shutaro Ozawa

  • Cetuximab, a Monoclonal Antibody Targeting the Epidermal Growth Factor Receptor, in Combination With Gemcitabine for Advanced Pancreatic Cancer: A Multicenter Phase II Trial

    Henry Q. Xiong;Arthur Rosenberg;Albert LoBuglio;William Schmidt

  • Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas.

    F. R. Spitz;J. L. Abbruzzese;Jeffrey E Lee;Peter W Pisters

  • A Phase I/II Trial of Intratumoral Endoscopic Ultrasound Injection of ONYX-015 with Intravenous Gemcitabine in Unresectable Pancreatic Carcinoma

    J Randolph Hecht;Rudolph Bedford;James L Abbruzzese;Sandeep Lahoti

  • Body Mass Index and Risk, Age of Onset, and Survival in Patients With Pancreatic Cancer

    Donghui Li;Jeffrey S. Morris;Jun Liu;Manal M. Hassan

Frequent Co-Authors

Robert A. Wolff
Robert A. Wolff The University of Texas MD Anderson Cancer Center
Douglas B. Evans
Douglas B. Evans Medical College of Wisconsin
Huamin Wang
Huamin Wang The University of Texas MD Anderson Cancer Center
Jeffrey E. Lee
Jeffrey E. Lee The University of Texas MD Anderson Cancer Center
Peter W.T. Pisters
Peter W.T. Pisters The University of Texas MD Anderson Cancer Center
Christopher H. Crane
Christopher H. Crane Memorial Sloan Kettering Cancer Center
Jason B. Fleming
Jason B. Fleming The University of Texas MD Anderson Cancer Center
Michael J. Overman
Michael J. Overman The University of Texas MD Anderson Cancer Center
Kenneth R. Hess
Kenneth R. Hess The University of Texas MD Anderson Cancer Center
Jean Nicolas Vauthey
Jean Nicolas Vauthey The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in Medicine involves a variety of educational pathways, many of which are now accessible online. In addition to traditional medical degrees, there are several related online programs that can lead to rewarding healthcare careers. These options are especially useful for students seeking affordability and flexibility.

For those interested in managing healthcare data and records, an online health information management degree offers essential training in data privacy, medical records, and informatics.

Another valuable credential is available through billing and coding classes online, which prepare students for the critical administrative side of healthcare services.

Nursing also presents abundant opportunities for online study. Prospective nurse practitioners may want to explore the cheapest fnp programs to become advanced practice nurses. Alternatively, those aiming for a registered nurse career might consider the cheapest bsn programs online to earn a Bachelor of Science in Nursing.

These alternative online degrees and certifications can open doors to specialized roles within the healthcare industry—even if you decide not to pursue a traditional MD.

Best Scientists Citing James L. Abbruzzese

Trending Scientists

Recently Published Articles